Evaluation of Medetomidine Dose Variations on Tiletamine-Zolazepam and Tramadol Anesthetic Combination in Dogs

This study evaluated the effects of varying medetomidine doses on a tiletamine-zolazepam and tramadol anesthetic combination in dogs. The objective was to assess how medetomidine influences anesthesia depth, cardiovascular function, and recovery quality. Dogs were assigned to one of three treatment groups: tiletamine-zolazepam and tramadol without medetomidine (TZT), additional 10 µg/kg medetomidine (TZTM10), or additional 20 µg/kg medetomidine (TZTM20). Each dog received an intramuscular injection of 0.1 mL/kg of the designated solution. The formulation for TZT contained 25 mg/mL tiletamine and zolazepam and 40 mg/mL tramadol, while TZTM10 and TZTM20 received the same solution with additional medetomidine at 100 and 200 µg/mL, respectively. Onset time, anesthetic time, analgesic time, recovery quality, and physiological parameters, including heart rate, blood pressure, respiratory rate, oxygen saturation, and body temperature, were evaluated. Medetomidine extended analgesic time in a dose-dependent manner and improved recovery quality while maintaining stable respiratory function. While TZT provided adequate anesthesia for minor non-invasive procedures, the inclusion of medetomidine in TZTM resulted in enhanced anesthetic stability for simple surgical procedures such as gonadectomy. These findings suggest that TZTM20 is a viable anesthetic protocol, though careful patient monitoring remains essential due to its cardiovascular effects.